Pacifica, CA, United States of America

Glen Eugene Mikesell

USPTO Granted Patents = 17 



Average Co-Inventor Count = 3.6

ph-index = 7

Forward Citations = 308(Granted Patents)


Location History:

  • Hamilton, NJ (US) (2005)
  • Fremont, CA (US) (2020)
  • Pacifica, CA (US) (2007 - 2021)

Company Filing History:


Years Active: 2005-2021

Loading Chart...
Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents

Title: The Innovative Mind of Glen Eugene Mikesell: A Leader in Biopharmaceutical Patents

Introduction

Glen Eugene Mikesell, based in Pacifica, California, is a prominent inventor in the field of biopharmaceuticals, boasting an impressive portfolio of 17 patents. His innovative contributions have advanced the understanding of immune modulation, creating new avenues for therapeutic interventions.

Latest Patents

Mikesell's latest patents include groundbreaking work on the fusions of antibodies to CD38, where he presents a polypeptide construct designed to improve therapeutic efficacy by targeting specific cell surface antigens. His other significant patent involves BSL2v2c2-Ig polypeptides, which provide foundational tools for modulating immune or inflammatory responses, particularly in T-cells. This invention showcases the potential of isolated B7-related polypeptides and their applications in immunomodulation, offering exciting possibilities for both human and animal health.

Career Highlights

Throughout his career, Mikesell has been associated with renowned companies such as Bristol-Myers Squibb Company and Teva Pharmaceuticals Australia Pty Ltd. His experiences in these prominent organizations have undoubtedly contributed to his expertise and innovation in biopharmaceutical research and development.

Collaborations

Mikesell has also collaborated with notable colleagues, including Han Chang and Robert Peach. These partnerships reflect the collaborative spirit of the scientific community and underscore the shared commitment to advancing medical science and improving patient outcomes.

Conclusion

Glen Eugene Mikesell's work exemplifies the dynamic nature of innovation within the biopharmaceutical sector. With a robust patent portfolio and a commitment to groundbreaking research, his contributions continue to impact immune therapies and beyond. The future holds much promise as he pursues further advancements in this vital field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…